![](/host-microbe/sites/center.host-microbe/files/styles/news_event_236x180/public/2022-11/Screen%20Shot%202022-11-08%20at%2017.12.42_0.png?itok=g0chk_Ez)
Date:
Oct 27, 2022
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
New Article published in Nature Cancer - Amit Lab